EXCLUSIVE: Stem Cell Focused BioRestorative Ventures Into $63B Aesthetics Market Via Supply Agreement With Evolutionary Biologics

BioRestorative Therapies Inc BRTX has entered into a supply agreement with Evolutionary Biologics, a supplier of biologic-based cosmetics. 

Under the supply agreement, BioRestorative, using its cGMP ISO-7 certified clean room, will manufacture tissue-based biologics for Evolutionary Biologics for cosmetic and aesthetic applications.

The initial order of 5,000 vials represents a controlled launch and is expected to have a positive financial impact.

The first-generation product formulated and manufactured is an umbilical cord tissue extract that is highly enriched with factors that address the signs of aging.

These factors include cytokines, chemokines, growth factors, and exosomes, which are known to play important roles as communication mediators between cells and have been found to have certain anti-aging effects on the skin.

Founded in 2020 by former L'Oreal President Jim Morrison, Evolutionary Biologics is a supplier of cosmetic-focused biologics for plastic surgeons, dermatologists, and medical spas in the U.S. 

"Leveraging our ISO-7 certified clean room to formulate and manufacture a commercial product in the $62.8 billion global aesthetics market is not only a thrilling opportunity, but it allows us to scale and drive efficiencies going forward as we seek to expand our commercial business model...", stated Lance Alstodt, CEO of BioRestorative.

In June, 

BioRestorative Therapies announced that the independent Data Safety Monitoring Board unanimously recommended continuing its Phase 2 trial to treat chronic lumbar disc disease study under the current protocol version with no changes.

The treated patients will receive BRTX-100, a product formulated from autologous (or a person's own) hypoxic cultured mesenchymal stem cells collected from the patient's bone marrow and autologous platelet lysate.

Price Action: BRTX shares closed at $1.86 on Monday.